MCID: KWS002
MIFTS: 67

Kawasaki Disease

Categories: Genetic diseases, Rare diseases, Cardiovascular diseases, Bone diseases, Immune diseases

Aliases & Classifications for Kawasaki Disease

MalaCards integrated aliases for Kawasaki Disease:

Name: Kawasaki Disease 54 12 50 25 56 71 52 41 3 14
Mucocutaneous Lymph Node Syndrome 12 50 24 25 56 71 42 69
Infantile Polyarteritis 24 71 69
Kawasaki Syndrome 50 25 3
Acute Febrile Mucocutaneous Lymph Node Syndrome 25 29
Kawasaki Disease, Susceptibility to 24 13
Kd 25 3
Acute Febrile Mucocutaneous Lymph Node Syndrome [mcls] 12
Acute Febrile Mcls 12
Kawasaki's Disease 12
Mlns 12
Kwd 71

Characteristics:

Orphanet epidemiological data:

56
kawasaki disease
Inheritance: Multigenic/multifactorial; Age of onset: Adolescent,Adult,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



Summaries for Kawasaki Disease

OMIM : 54
Kawasaki disease is an acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy (Kawasaki, 1967). Coronary artery aneurysms develop in 15 to 25% of those left untreated (11,12:Kato et al., 1975, 1996), making Kawasaki disease the leading cause of acquired heart disease among children in developed countries. Treatment with intravenous immunoglobulin (IVIG) abrogates the inflammation in approximately 80% of affected individuals and reduces the aneurysm rate to less than 5%. Cardiac sequelae of the aneurysms include ischemic heart disease, myocardial infarction, and sudden death. Epidemiologic features such as seasonality and clustering of cases suggested an infectious trigger, although no pathogen had been isolated. Several lines of evidence suggested the importance of genetic factors in disease susceptibility and outcome. First, the incidence of Kawasaki disease is 10 to 20 times higher in Japan than in Western countries (Cook et al., 1989). Second, the risk of Kawasaki disease in sibs of affected children is 10 times higher than in the general population, and the incidence of Kawasaki disease in children born to parents with a history of Kawasaki disease is twice as high as that in the general population (Fujita et al., 1989; Uehara et al., 2003). Hata and Onouchi (2009) reviewed current knowledge on Kawasaki disease, including epidemiology, genomewide linkage analysis, and molecular genetics. (611775)

MalaCards based summary : Kawasaki Disease, also known as mucocutaneous lymph node syndrome, is related to hemophagocytic lymphohistiocytosis and polyarteritis nodosa, and has symptoms including diarrhea, migraine and jaundice. An important gene associated with Kawasaki Disease is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Aspirin and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include lymph node, heart and tongue, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 kawasaki disease is a disease that involves inflammation of the blood vessels. it is typically diagnosed in young children, but older children and adults can also develop this condition. kawasaki disease begins with a fever that lasts at least five days. other classic symptoms may include red eyes, lips, and mouth; rash; swollen and red hands and feet; and swollen lymph nodes. sometimes the disease affects the coronary arteries which carry oxygen-rich blood to the heart, which can lead to serious heart problems. kawasaki disease occurs most often in people of asian and pacific island descent. the cause of kawasaki disease is unknown. an infection along with genetic factors may be involved. treatment includes intravenous gamma globulin and high doses of aspirin in a hospital setting.prognosis is generally very good, but in cases of heart complications it depends on the severity of the coronary disease.  last updated: 3/9/2017

UniProtKB/Swiss-Prot : 71 Kawasaki disease: An acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy.

MedlinePlus : 41 kawasaki disease is a rare childhood disease. it makes the walls of the blood vessels in the body become inflamed. it can affect any type of blood vessel, including the arteries, veins, and capillaries. no one knows what causes kawasaki disease. symptoms include high fever that lasts longer than 5 days swollen lymph nodes in the neck a rash on the mid-section and genital area red, dry, cracked lips and a red, swollen tongue red, swollen palms of the hands and soles of the feet redness of the eyes kawasaki disease can't be passed from one child to another. there is no single test. to diagnose it, doctors look at the signs and symptoms. they may also use an echocardiogram or other tests. it is mainly treated with medicines. rarely, medical procedures and surgery also may be used for children whose coronary arteries are affected. kawasaki disease can't be prevented. however, most children who develop the disease fully recover - usually within weeks of getting signs and symptoms. further problems are rare. nih: national heart, lung, and blood institute

CDC : 3 Kawasaki disease (KD), also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age. The disease was first described in Japan by Tomisaku Kawasaki in 1967, and the first cases outside of Japan were reported in Hawaii in 1976. Clinical signs include fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat.

Genetics Home Reference : 25 Kawasaki disease is a sudden and time-limited (acute) illness that affects infants and young children. Affected children develop a prolonged fever lasting several days, a skin rash, and swollen lymph nodes in the neck (cervical lymphadenopathy). They also develop redness in the whites of the eyes (conjunctivitis) and redness (erythema) of the lips, lining of the mouth (oral mucosa), tongue, palms of the hands, and soles of the feet.

Disease Ontology : 12 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located in body, has symptom fever, has symptom congestion of ocular conjunctivae, has symptom reddening of lips, has symptom reddening of oral cavity, has symptom protuberance of tongue papillae and has symptom edema of extremities.

Wikipedia : 72 Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a disease in which blood vessels... more...

Related Diseases for Kawasaki Disease

Diseases related to Kawasaki Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
id Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 31.0 IL10 IL6 TNF
2 polyarteritis nodosa 30.9 ALB CRP TNF
3 ischemic heart disease 30.5 ALB CRP IL6
4 pyelonephritis 30.0 CRP IL10 NPPB TNF
5 atherosclerosis 29.7 CCL2 IL10 IL6 MMP3 MMP9 TNF
6 alopecia 29.7 ALB CCL2 IL10 IL6 TNF
7 rheumatoid arthritis 28.4 CCL2 CRP IL10 IL6 MMP3 S100A12
8 chickenpox 28.4 CCL2 CRP ELANE SELE SELL TNF
9 systemic lupus erythematosus 28.2 ALB BLK CCL2 CRP FCGR2A IL10
10 asthma 26.9 ADM ELANE IL10 IL6 MMP9 SELE
11 myocardial infarction 26.1 ADM ALB CCL2 CRP IL10 IL6
12 abl1 kd-related altered drug metabolism 11.8
13 krabbe disease 11.3
14 vasculitis 11.2
15 macrophage activation syndrome 11.1
16 spinal and bulbar muscular atrophy of kennedy 10.9
17 pure autonomic failure 10.9 IL10 TNF
18 smarca4-deficient sarcoma of thorax 10.9 IL6 TNF
19 congenital dyserythropoietic anemia 10.9 ALB TNF
20 acute ackee fruit intoxication 10.8 IL10 TNF
21 ribbing disease 10.8 MMP3 MMP9
22 malignant hyperthermia susceptibility 1 10.8
23 collagenopathy type 2 alpha 1 10.8 CRP IL6
24 epstein-barr virus hepatitis 10.8 CRP IL6 TNF
25 kniest dysplasia 10.8
26 petrous apex meningioma 10.8 CRP MMP9 TNF
27 central nervous system leiomyosarcoma 10.8 CRP IL6 TNF
28 cicatricial lagophthalmos 10.8 CRP IL6 TNF
29 benign neonatal seizures 10.8 CRP IL6 TNF
30 pityriasis rosea 10.8 IL6 MMP9 TNF
31 arthus reaction 10.8 ALB CRP TNF
32 myeloid sarcoma 10.8 CRP IL6 TNF
33 ethmoid sinus adenocarcinoma 10.7 IL10 IL6 TNF
34 early congenital syphilis 10.7 CRP IL6 TNF
35 drug rash with eosinophilia and systemic symptoms 10.7 IL10 IL6 MMP9
36 megaloblastic anemia 10.7 CRP IL10 TNF
37 breast disease 10.7 CRP IL6 TNF
38 phlyctenulosis 10.7 IL10 IL6 TNF
39 cyclosporiasis 10.7 IL10 IL6 TNF
40 early-onset zonular cataract 10.7 IL10 IL6 TNF
41 primary biliary cirrhosis 10.7 IL10 IL6 TNF
42 hyperlipoproteinemia type iv 10.7 ALB CRP IL6
43 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.7 CRP IL10 IL6
44 aortic arch interruption 10.7 IL6 TNF
45 ulcerative colitis 10.7 IL10 IL6 TNF
46 antigen-peptide-transporter 2 deficiency 10.7 CCL2 IL6 TNF
47 bladder sarcoma 10.7 ALB IL6 TNF
48 stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features 10.7 CCL2 IL6 TNF
49 spindle cell hemangioma 10.7 FCGR2A IL10 TNF
50 tumefactive multiple sclerosis 10.7 CCL2 MMP9 TNF

Graphical network of the top 20 diseases related to Kawasaki Disease:



Diseases related to Kawasaki Disease

Symptoms & Phenotypes for Kawasaki Disease

Clinical features from OMIM:

611775

Human phenotypes related to Kawasaki Disease:

56 32 (show all 37)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diarrhea 56 32 frequent (33%) Frequent (79-30%) HP:0002014
2 migraine 56 32 occasional (7.5%) Occasional (29-5%) HP:0002076
3 jaundice 56 32 occasional (7.5%) Occasional (29-5%) HP:0000952
4 ptosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000508
5 proteinuria 56 32 hallmark (90%) Very frequent (99-80%) HP:0000093
6 irritability 56 32 occasional (7.5%) Occasional (29-5%) HP:0000737
7 fatigue 56 32 frequent (33%) Frequent (79-30%) HP:0012378
8 pericarditis 56 32 frequent (33%) Frequent (79-30%) HP:0001701
9 arthritis 56 32 frequent (33%) Frequent (79-30%) HP:0001369
10 arrhythmia 56 32 occasional (7.5%) Occasional (29-5%) HP:0011675
11 cholecystitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001082
12 fever 56 32 frequent (33%) Frequent (79-30%) HP:0001945
13 congestive heart failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001635
14 abdominal pain 56 32 frequent (33%) Frequent (79-30%) HP:0002027
15 lymphadenopathy 56 32 hallmark (90%) Very frequent (99-80%) HP:0002716
16 edema 56 32 frequent (33%) Frequent (79-30%) HP:0000969
17 conjunctivitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0000509
18 vasculitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002633
19 skin rash 56 32 hallmark (90%) Very frequent (99-80%) HP:0000988
20 arthralgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002829
21 erythema 56 32 hallmark (90%) Very frequent (99-80%) HP:0010783
22 myocarditis 56 32 occasional (7.5%) Occasional (29-5%) HP:0012819
23 leukocytosis 56 32 frequent (33%) Frequent (79-30%) HP:0001974
24 glossitis 56 32 frequent (33%) Frequent (79-30%) HP:0000206
25 cranial nerve paralysis 56 32 occasional (7.5%) Occasional (29-5%) HP:0006824
26 meningitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001287
27 nausea and vomiting 56 32 occasional (7.5%) Occasional (29-5%) HP:0002017
28 hepatitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0012115
29 abnormality of the heart valves 56 32 frequent (33%) Frequent (79-30%) HP:0001654
30 dilatation of the ascending aorta 56 32 occasional (7.5%) Occasional (29-5%) HP:0005111
31 cheilitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0100825
32 recurrent pharyngitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0100776
33 abnormality of nail color 56 32 frequent (33%) Frequent (79-30%) HP:0100643
34 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0011658
35 aseptic leukocyturia 56 32 occasional (7.5%) Occasional (29-5%) HP:0100586
36 interstitial pulmonary disease 56 Occasional (29-5%)
37 interstitial pulmonary abnormality 32 occasional (7.5%) HP:0006530

UMLS symptoms related to Kawasaki Disease:


angina pectoris, chest pain, edema, exanthema, pruritus

MGI Mouse Phenotypes related to Kawasaki Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 IL6 ITPKC MMP3 MMP9 MYD88 SELE
2 immune system MP:0005387 10.22 ADM BLK CCL2 CRP ELANE FCGR2A
3 homeostasis/metabolism MP:0005376 10.18 ADM ALB CRP ELANE IL10 IL6
4 cardiovascular system MP:0005385 10.16 ADM CRP IL10 IL6 MMP9 MYD88
5 endocrine/exocrine gland MP:0005379 10.13 ALB BLK IL10 IL6 ITPKC MYD88
6 neoplasm MP:0002006 9.81 ALB ELANE IL10 IL6 MMP9 MYD88
7 liver/biliary system MP:0005370 9.8 ADM ALB IL10 IL6 SELE SELL
8 reproductive system MP:0005389 9.61 BLK HSPD1 IL10 IL6 MMP9 MYD88
9 respiratory system MP:0005388 9.28 ADM IL10 IL6 MMP9 MYD88 SELE

Drugs & Therapeutics for Kawasaki Disease

Drugs for Kawasaki Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
4 Analgesics Phase 4,Phase 2
5 Analgesics, Non-Narcotic Phase 4,Phase 2
6 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
7 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
8 Antipyretics Phase 4
9 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Cyclooxygenase Inhibitors Phase 4
11 Fibrinolytic Agents Phase 4
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Platelet Aggregation Inhibitors Phase 4
14 Calcium, Dietary Phase 4,Phase 2,Phase 1
15 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
16 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
17 Adrenergic beta-Antagonists Phase 4
18 Angiotensin II Type 1 Receptor Blockers Phase 4
19 Angiotensin Receptor Antagonists Phase 4
20 Angiotensin-Converting Enzyme Inhibitors Phase 4
21 Angiotensinogen Phase 4
22 Antihypertensive Agents Phase 4
23 calcium channel blockers Phase 4
24 diuretics Phase 4
25 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1
26 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
27 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1
28
Infliximab Approved Phase 3,Phase 2,Phase 1 170277-31-3
29
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31 Autonomic Agents Phase 3,Phase 1
32 Protective Agents Phase 3,Phase 1
33 Dermatologic Agents Phase 3,Phase 2,Phase 1
34 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
35 Radiopharmaceuticals Phase 3,Phase 1,Phase 2
36 Technetium Tc 99m Sestamibi Phase 3,Phase 1,Phase 2
37 Pharmaceutical Solutions Phase 3,Phase 2
38 glucocorticoids Phase 3
39 Antiemetics Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 Hormone Antagonists Phase 3
42 Hormones Phase 3
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
44 Methylprednisolone acetate Phase 3
45 Methylprednisolone Hemisuccinate Phase 3
46 Neuroprotective Agents Phase 3
47 Prednisolone acetate Phase 3
48 Prednisolone hemisuccinate Phase 3
49 Prednisolone phosphate Phase 3
50 alanine Nutraceutical Phase 3

Interventional clinical trials:

(show all 41)

id Name Status NCT ID Phase Drugs
1 Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease Completed NCT01524939 Phase 4 immunoglobulin G
2 Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease Completed NCT00190580 Phase 4 valsartan;Conventional antihypertensive drugs
3 A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Recruiting NCT02951234 Phase 4
4 Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial Completed NCT02298062 Phase 3 Infliximab;IVIG
5 Different Doses of IVIG for Kawasaki Disease Completed NCT02439996 Phase 3 IVIG (1g/kg,once);IVIG (1g/kg,twice);IVIG (2g/kg.once)
6 A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Completed NCT00162032 Phase 3 Sestamibi
7 Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Completed NCT00760435 Phase 3 Infliximab;Placebo
8 Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease Completed NCT01596335 Phase 3 TA-650;Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
9 Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network Completed NCT00132080 Phase 3 Steroids
10 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
11 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
12 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
13 KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Recruiting NCT03065244 Phase 3 IVIG;Infliximab
14 A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Recruiting NCT03200561 Phase 3 Prednisolone
15 Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Unknown status NCT02114099 Phase 2 Atorvastatin
16 Prevention of Coronary Aneurysms in Kawasaki Syndrome Completed NCT00000520 Phase 2 immunoglobulins, intravenous;aspirin
17 A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Completed NCT00162045 Phase 1, Phase 2 Technetium Tc99m Sestamibi
18 Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Recruiting NCT01431105 Phase 1, Phase 2 Atorvastatin
19 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Recruiting NCT02179853 Phase 1, Phase 2 Anakinra
20 Anakinra and Kawasaki Disease Recruiting NCT02390596 Phase 2 Anakinra
21 Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease Recruiting NCT01917721 Phase 2 Doxycycline;Standard care
22 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Recruiting NCT03174964 Phase 2 IVIg
23 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Recruiting NCT03174951 Phase 2 IVIg
24 Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study Recruiting NCT02219165 Phase 2 Intravenous human immunoglobulin;Albumin
25 Etanercept in Kawasaki Disease Active, not recruiting NCT00841789 Phase 2 Etanercept;Placebo
26 Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Withdrawn NCT00305201 Phase 2 pravastatin
27 Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Withdrawn NCT02980263 Phase 2 Canakinumab
28 Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Unknown status NCT00861848 Phase 1
29 Infliximab (Remicade) for Patients With Acute Kawasaki Disease Completed NCT00271570 Phase 1 Infliximab (Remicade)
30 Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease Unknown status NCT02359643 Aspirin
31 Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease Completed NCT01440075
32 Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Completed NCT02317913
33 Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States Completed NCT00875641
34 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
35 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
36 Etiology Study of Kawasaki Disease Recruiting NCT00154596
37 Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. Recruiting NCT02771288
38 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
39 Tobacco Cessation Intervention Study for Oral Diseases Recruiting NCT02737176
40 Measurement of Antibodies in Adults With a History of Kawasaki Disease Active, not recruiting NCT02853266
41 Identification of Viruses Associated With Diseases of Unknown Cause Enrolling by invitation NCT00359268

Search NIH Clinical Center for Kawasaki Disease

Cochrane evidence based reviews: mucocutaneous lymph node syndrome

Genetic Tests for Kawasaki Disease

Genetic tests related to Kawasaki Disease:

id Genetic test Affiliating Genes
1 Acute Febrile Mucocutaneous Lymph Node Syndrome 29
2 Kawasaki Disease, Susceptibility to 24 ITPKC

Anatomical Context for Kawasaki Disease

MalaCards organs/tissues related to Kawasaki Disease:

39
Lymph Node, Heart, Tongue, Eye, Skin, Endothelial, Testes

Publications for Kawasaki Disease

Articles related to Kawasaki Disease:

(show top 50) (show all 1139)
id Title Authors Year
1
Gallbladder Hydrops Associated With Kawasaki Disease: A Case Report and Literature Review. ( 28952362 )
2017
2
FCN1 (M-ficolin), which directly associates with immunoglobulin G1, is a molecular target of intravenous immunoglobulin therapy for Kawasaki disease. ( 28900133 )
2017
3
Evaluation of longitudinal and radial left ventricular functions using two- and three-dimensional echocardiography before and after intravenous immunoglobulin administration in patients with acute Kawasaki disease. ( 28892213 )
2017
4
Evaluation of myocardial deformation in patients with Kawasaki disease using speckle-tracking echocardiography during mid-term follow-up - CORRIGENDUM. ( 28532518 )
2017
5
Off-Pump Double Coronary Artery Bypass in a 14-Year-Old With Kawasaki Disease. ( 28935322 )
2017
6
Pulmonary presentation of Kawasaki disease-A diagnostic challenge. ( 28950425 )
2017
7
Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children. ( 28461824 )
2017
8
Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review. ( 28562511 )
2017
9
Z-score of Mitral Annular Plane Systolic Excursion is a Useful Indicator of Evaluation of Left Ventricular Function in Patients with Acute-Phase Kawasaki Disease. ( 28456832 )
2017
10
Difficult diagnosis of Kawasaki disease in a patient with giant coronary artery aneurysms. ( 28895991 )
2017
11
Fever without a source: evolution of a diagnosis from Kawasaki disease to acute myelogenous leukaemia. ( 28478386 )
2017
12
Association of Toll-like receptor 2-positive monocytes with coronary artery lesions and treatment nonresponse in Kawasaki disease. ( 28861111 )
2017
13
Retrospective analysis of risk factors associated with Kawasaki disease in China. ( 28514726 )
2017
14
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease. ( 28079915 )
2017
15
Simultaneous development of Kawasaki disease following acute human adenovirus infection in monozygotic twins: A case report. ( 28511718 )
2017
16
Elevated serum YKL-40 levels in patients with Kawasaki disease. ( 27881022 )
2017
17
A plasma mir-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs. ( 28467514 )
2017
18
Pathogenetic determinants in Kawasaki disease: the haematological point of view. ( 28063205 )
2017
19
Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker. ( 28417923 )
2017
20
Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. ( 28151979 )
2017
21
Novel Risk Assessment Tool for Immunoglobulin-Resistance in Kawasaki Disease: Application Using a Random Forest Classifier. ( 28441265 )
2017
22
High-dose aspirin for Kawasaki disease: outdated myth or effective aid? ( 28079513 )
2017
23
Intestinal Pseudo-Obstruction as the Presenting Manifestation of Kawasaki Disease. ( 28417227 )
2017
24
Expression of Fc<gamma>Rs on monocytes among Kawasaki disease patients with coronary artery lesions. ( 28147297 )
2017
25
The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease. ( 28081636 )
2017
26
Evidence of correlation between TGFBR2 gene expression mediated by NF-kB signaling pathways and Kawasaki disease in children. ( 28922909 )
2017
27
"Giant within a giant": a case of typical Kawasaki disease with a giant coronary aneurysm and a large coronary thrombus - a rare case report. ( 28835313 )
2017
28
Nationwide Survey of Patients With Giant Coronary Aneurysm Secondary to Kawasaki Disease 1999-2010 in Japan. ( 28855435 )
2017
29
Allograft Inflammatory Factor-1 Links T-Cell Activation, Interferon Response, and Macrophage Activation in Chronic Kawasaki Disease Arteritis. ( 28505365 )
2017
30
Anti-inflammatory effect of resveratrol in human coronary arterial endothelial cells via induction of autophagy: implication for the treatment of Kawasaki disease. ( 28069066 )
2017
31
Identifying genetic hypomethylation and upregulation of toll-like receptors in Kawasaki disease. ( 28061462 )
2017
32
Parotitis as an Initial Symptom of Kawasaki Disease. ( 28593063 )
2017
33
Distinct Distribution of Immunocytes in a Retropharyngeal Lymphadenopathy Associated with Kawasaki Disease: A Case Study Compared with Tonsillitis. ( 28467980 )
2017
34
A Case of Hemophagocytic Lymphohistiocytosis and Kawasaki Disease: Concurrent or Overlapping Diagnoses? ( 28452857 )
2017
35
Male-specific association of the FCGR2A His167Arg polymorphism with Kawasaki disease. ( 28886140 )
2017
36
Infantile incomplete Kawasaki disease mimicking cervical purulent lymphadenitis with coronary artery aneurysm. ( 28786205 )
2017
37
Reaction of the BCG Scar in the Acute Phase of Kawasaki Disease in Mexican Children. ( 28498302 )
2017
38
1,25-Dihydroxyvitamin D3 regulates T lymphocyte proliferation through activation of P53 and inhibition of ERK1/2 signaling pathway in children with Kawasaki disease. ( 28925469 )
2017
39
Retrospective study of the impact of unrecognised Kawasaki disease, coronary aneurysm and ectasia. ( 28818354 )
2017
40
Clinical Manifestations of Kawasaki Disease Shock Syndrome. ( 28905639 )
2017
41
Prediction of Resistance to Intravenous Immunoglobulin in Children With Kawasaki Disease. ( 28062554 )
2017
42
Retrospective analysis of risk factors associated with Kawasaki disease in China. ( 28903347 )
2017
43
Kawasaki Disease and Labyrinthitis: An Underdiagnosed Complication. ( 28417110 )
2017
44
Atypical desquamation in a 2.5-year-old boy with Kawasaki disease: A case report. ( 28465804 )
2017
45
Clinical assessment of coronary arteries in Kawasaki disease: Focus on echocardiographic assessment. ( 28921836 )
2017
46
Correlation of HAMP gene polymorphisms and expression with the susceptibility and length of hospital stays in Taiwanese children with Kawasaki disease. ( 28881695 )
2017
47
Heart Transplantation in a Toddler with Cardiac Kawasaki Disease. ( 28473974 )
2017
48
Kawasaki Disease Presenting as Acute Intestinal Obstruction. ( 28694577 )
2017
49
Acute Complete Adult-onset Kawasaki Disease in a Middle-Aged Woman. ( 28903849 )
2017
50
Association of PECAM-1 Gene Polymorphisms with Kawasaki Disease in Chinese Children. ( 28512385 )
2017

Variations for Kawasaki Disease

Expression for Kawasaki Disease

Search GEO for disease gene expression data for Kawasaki Disease.

Pathways for Kawasaki Disease

Pathways related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 BLK CCL2 CRP ELANE FCGR2A IL10
2
Show member pathways
13.36 CCL2 IL10 IL6 MMP3 MMP9 MYD88
3
Show member pathways
12.86 CCL2 IL6 MMP9 SELE TNF
4
Show member pathways
12.85 CCL2 IL10 IL6 MYD88 TNF
5
Show member pathways
12.69 BLK IL6 MYD88 TIMP1 TNF
6
Show member pathways
12.58 CCL2 IL10 IL6 TIMP1 TNF
7 12.54 BLK CCL2 IL10 MYD88 TNF
8
Show member pathways
12.34 CCL2 IL6 MMP3 MMP9 TNF
9
Show member pathways
12.24 FCGR2A IL10 MYD88 TNF
10 12.22 FCGR2A HSPD1 IL10 IL6 MYD88 TNF
11 12.21 ELANE IL6 MMP3 MMP9
12 12.17 HSPD1 IL10 IL6 TNF
13 12.08 CCL2 MMP9 SELE TNF
14 12.01 CCL2 FCGR2A IL6 MMP9 TNF
15 11.99 FCGR2A IL10 IL6 SELL TNF
16 11.91 CCL2 IL6 SELE TNF
17
Show member pathways
11.9 ELANE MMP3 MMP9 TIMP1 TNF
18 11.87 CCL2 IL6 MMP3 TNF
19 11.84 CCL2 MMP3 MMP9 TIMP1
20 11.83 CCL2 IL6 MMP3 MMP9 SELE TNF
21
Show member pathways
11.79 CRP IL6 TIMP1
22 11.77 IL10 IL6 MYD88 TNF
23 11.76 IL10 IL6 SELL TNF
24 11.71 FCGR2A IL10 IL6 TNF
25 11.65 CCL2 IL6 MMP9 TIMP1 TNF
26 11.63 MMP3 MMP9 TIMP1
27
Show member pathways
11.63 IL6 MMP3 MMP9 SELE TNF
28 11.59 HSPD1 IL6 MYD88 TNF
29 11.56 CCL2 IL10 IL6 MMP3 MMP9 TIMP1
30 11.49 CCL2 IL10 IL6 TIMP1 TNF
31 11.45 BLK ELANE IL6 MMP9 TNF
32 11.35 IL10 IL6 TNF
33 11.34 CCL2 IL6 MMP9
34 11.28 IL10 IL6 TNF
35 11.25 ELANE MMP3 MMP9 SELE SELL
36 11.19 CCL2 IL10 IL6 TNF
37 11.18 CCL2 MMP9 MYD88 TIMP1
38 11.1 IL10 IL6 MYD88 SELE TNF
39 11.05 CRP IL6 TNF
40 10.79 CCL2 IL10 IL6 MYD88 SELE TNF

GO Terms for Kawasaki Disease

Cellular components related to Kawasaki Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 ADM ALB CCL2 CRP ELANE IL10
2 extracellular space GO:0005615 9.47 ADM ALB CCL2 CRP ELANE HSPD1

Biological processes related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.98 BLK IL6 MYD88 TNF
2 negative regulation of apoptotic process GO:0043066 9.98 ALB HSPD1 IL10 IL6 MMP9 MYD88
3 defense response to bacterium GO:0042742 9.97 ELANE IL10 S100A12 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 IL6 MYD88 S100A12 TNF
5 leukocyte migration GO:0050900 9.91 ELANE MMP9 SELE SELL TNF
6 cellular response to lipopolysaccharide GO:0071222 9.88 CCL2 IL10 IL6 TNF
7 aging GO:0007568 9.88 ADM CCL2 IL10 IL6 TIMP1
8 response to wounding GO:0009611 9.85 ADM CCL2 IL6
9 response to insulin GO:0032868 9.85 ADM IL10 IL6
10 defense response to Gram-positive bacterium GO:0050830 9.85 CRP IL6 MYD88 TNF
11 response to organic substance GO:0010033 9.84 ADM IL10 TIMP1 TNF
12 positive regulation of MAP kinase activity GO:0043406 9.83 ELANE S100A12 TNF
13 humoral immune response GO:0006959 9.82 CCL2 IL6 TNF
14 extracellular matrix disassembly GO:0022617 9.8 ELANE MMP3 MMP9 TIMP1
15 response to cold GO:0009409 9.79 ADM HSPD1 IL6
16 monocyte chemotaxis GO:0002548 9.79 CCL2 IL6 S100A12
17 cellular response to estradiol stimulus GO:0071392 9.77 CCL2 IL10 IL6
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 ELANE IL6 MYD88 TNF
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 CCL2 MYD88 TNF
20 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 IL10 MMP9 TNF
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL10 TNF
22 positive regulation of chemokine biosynthetic process GO:0045080 9.68 MYD88 TNF
23 branching involved in labyrinthine layer morphogenesis GO:0060670 9.67 ADM IL10
24 positive regulation of interleukin-6 production GO:0032755 9.67 HSPD1 IL6 MYD88 TNF
25 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.66 ELANE TNF
26 endothelial cell apoptotic process GO:0072577 9.66 IL10 TNF
27 response to peptidoglycan GO:0032494 9.65 IL6 MYD88
28 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.65 IL10 TIMP1
29 response to glucocorticoid GO:0051384 9.65 ADM CCL2 IL10 IL6 TNF
30 response to yeast GO:0001878 9.64 ELANE IL6
31 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 IL10 TNF
32 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.63 IL6 TNF
33 regulation of vascular endothelial growth factor production GO:0010574 9.6 CCL2 IL6
34 receptor biosynthetic process GO:0032800 9.58 IL10 TNF
35 leukocyte migration involved in inflammatory response GO:0002523 9.58 CCL2 ELANE SELE
36 negative regulation of chemokine biosynthetic process GO:0045079 9.57 ELANE IL6
37 inflammatory response GO:0006954 9.56 CCL2 CRP IL10 IL6 MYD88 S100A12
38 negative regulation of lipid storage GO:0010888 9.5 CRP IL6 TNF
39 negative regulation of growth of symbiont in host GO:0044130 9.46 ELANE IL10 MYD88 TNF
40 response to lipopolysaccharide GO:0032496 9.17 ADM CCL2 ELANE IL10 IL6 MYD88
41 neutrophil degranulation GO:0043312 10.08 ELANE FCGR2A MMP9 S100A12 SELL
42 positive regulation of apoptotic process GO:0043065 10.02 ADM HSPD1 IL6 MMP9 TNF

Molecular functions related to Kawasaki Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 9.5 ELANE MMP3 MMP9
2 protease binding GO:0002020 9.46 ELANE SELL TIMP1 TNF
3 receptor binding GO:0005102 9.43 ADM BLK CCL2 IL6 MYD88 NPPB
4 cytokine activity GO:0005125 9.02 CCL2 IL10 IL6 TIMP1 TNF
5 protein binding GO:0005515 10.21 ADM ALB BLK CRP ELANE FCGR2A

Sources for Kawasaki Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....